(378) Dextran-based T-cell expansion nanoparticles for ex vivo generation of efficacious CAR T cells
Introduction: Adoptive T cell therapy (ACT) using chimeric antigen receptor (CAR) engineered T cells has emerged as a promising form of immunotherapy, that is currently being expanded to multiple cancer types. A key step in CAR-T manufacturing is the activation and expansion of T cells, which while necessary, may hamper T cell fitness and reduce in vivo persistence.
Learning Objectives:
demonstrate nano-sized artificial antigen presenting cells interacting with primary T cell
